Literature DB >> 20707820

Vaccines based on whole recombinant Saccharomyces cerevisiae cells.

Andressa Ardiani1, Jack P Higgins, James W Hodge.   

Abstract

The ultimate goal of therapeutic vaccines is to activate and exploit the patient's own immune system to vigorously and dynamically seek and eradicate established malignant or virally infected cells. Therapeutic vaccines also offer the potential for preventing disease recurrence. Saccharomyces cerevisiae-based vaccines, where the yeast is engineered to express viral or tumor antigens, represent an ideal therapeutic approach due to their ability to stimulate tumor- or viral-specific CD4(+) and CD8(+) T-cell responses that are capable of reducing disease burden. This review describes preclinical and clinical studies supporting the development of S. cerevisiae-based therapeutic vaccines for the treatment of cancer and viral diseases, as well as multimodal strategies in which therapeutic vaccines are combined with cytotoxic drugs to achieve a greater clinical response. Journal compilation
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20707820      PMCID: PMC7295092          DOI: 10.1111/j.1567-1364.2010.00665.x

Source DB:  PubMed          Journal:  FEMS Yeast Res        ISSN: 1567-1356            Impact factor:   2.796


  43 in total

Review 1.  Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses.

Authors:  Andrew C Stubbs; Cara C Wilson
Journal:  Curr Opin Mol Ther       Date:  2002-02

2.  Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.

Authors:  Janet M D Plate; Aileen E Plate; Susan Shott; Susan Bograd; Jules E Harris
Journal:  Cancer Immunol Immunother       Date:  2005-03-22       Impact factor: 6.968

3.  Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.

Authors:  P Clarke; J Mann; J F Simpson; K Rickard-Dickson; F J Primus
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

4.  Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.

Authors:  Michael B Bernstein; Mala Chakraborty; Elizabeth K Wansley; Zhimin Guo; Alex Franzusoff; Sven Mostböck; Helen Sabzevari; Jeffrey Schlom; James W Hodge
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

5.  The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.

Authors:  Mala Chakraborty; Elizabeth K Wansley; Jorge A Carrasquillo; Sarah Yu; Chang H Paik; Kevin Camphausen; Michael D Becker; William F Goeckeler; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

6.  Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.

Authors:  Amanda L Boehm; Jack Higgins; Alex Franzusoff; Jeffrey Schlom; James W Hodge
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

7.  Resistance of murine lung tumors to xenobiotic-induced cytotoxicity.

Authors:  P G Forkert; A Parkinson; L G Thaete; A M Malkinson
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

Review 8.  Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.

Authors:  James W Hodge; Chandan Guha; Jacques Neefjes; James L Gulley
Journal:  Oncology (Williston Park)       Date:  2008-08       Impact factor: 2.990

9.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

Authors:  Anna K Nowak; Bruce W S Robinson; Richard A Lake
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  Saccharomyces cerevisiae: a versatile eukaryotic system in virology.

Authors:  Rui P Galao; Nicoletta Scheller; Isabel Alves-Rodrigues; Tanja Breinig; Andreas Meyerhans; Juana Díez
Journal:  Microb Cell Fact       Date:  2007-10-10       Impact factor: 5.328

View more
  21 in total

Review 1.  Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity.

Authors:  Maurizio Rinaldi; Roberto Perricone; Miri Blank; Carlo Perricone; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

2.  Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.

Authors:  Bruno Douradinha; Viviane C B Reis; Matthew B Rogers; Fernando A G Torres; Jared D Evans; Ernesto T A Marques
Journal:  Bioengineered       Date:  2013-09-05       Impact factor: 3.269

Review 3.  Exploiting fungal cell wall components in vaccines.

Authors:  Stuart M Levitz; Haibin Huang; Gary R Ostroff; Charles A Specht
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

4.  Recombinant Protein Production and Purification of Insoluble Proteins.

Authors:  Neus Ferrer-Miralles; Paolo Saccardo; José Luis Corchero; Elena Garcia-Fruitós
Journal:  Methods Mol Biol       Date:  2022

5.  Yeast (Saccharomyces cerevisiae) Polarizes Both M-CSF- and GM-CSF-Differentiated Macrophages Toward an M1-Like Phenotype.

Authors:  Michelle Seif; Anja Philippi; Frank Breinig; Alexandra K Kiemer; Jessica Hoppstädter
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

6.  Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.

Authors:  Peter Joseph DeMaria; Marijo Bilusic; Deric M Park; Christopher R Heery; Renee N Donahue; Ravi A Madan; Mohammad Hadi Bagheri; Julius Strauss; Victoria Shen; Jennifer L Marté; Seth M Steinberg; Jeffrey Schlom; Mark R Gilbert; James L Gulley
Journal:  Oncologist       Date:  2021-03-09

7.  Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit.

Authors:  Marina Arnold; Vijay Durairaj; Egbert Mundt; Katja Schulze; Karin D Breunig; Sven-Erik Behrens
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

8.  Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Authors:  Duane H Hamilton; Mary T Litzinger; Alessandra Jales; Bruce Huang; Romaine I Fernando; James W Hodge; Andressa Ardiani; David Apelian; Jeffrey Schlom; Claudia Palena
Journal:  Oncotarget       Date:  2013-10

9.  Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases.

Authors:  Tomohiro Shigemori; Mitsuru Nagayama; Junki Yamada; Natsuko Miura; Suganya Yongkiettrakul; Kouichi Kuroda; Tohoru Katsuragi; Mitsuyoshi Ueda
Journal:  FEBS Open Bio       Date:  2013-10-29       Impact factor: 2.693

10.  Recombinant Kluyveromyces lactis expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP5 elicits mucosal and cell-mediated immune responses in mice.

Authors:  Haiyan Zhao; Yalan Wang; Zhitao Ma; Yongqiang Wang; Wen-hai Feng
Journal:  J Vet Sci       Date:  2013-12-27       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.